Eletriptan

Eletriptan is a pivotal pharmaceutical active ingredient and analytical reference standard in the treatment of migraine headaches, functioning as a selective 5-HT₁B/1D receptor agonist that constricts dilated cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. As the hydrobromide salt, Eletriptan is distinguished among triptans by its high lipophilicity (LogP 4.839), which contributes to its rapid central nervous system penetration and established efficacy as the most efficacious oral triptan for 2-hour pain freedom—the highest clinical benchmark for novel agent comparison. Eletriptan serves as both the API for commercial Relpax® production and as a reference standard for analytical method development, method validation (AMV), quality control (QC) applications for Abbreviated New Drug Applications (ANDA), and during commercial production. As an indole-based triptan, Eletriptan offers researchers and pharmaceutical manufacturers a well-characterized scaffold with linear pharmacokinetics that simplifies dose-response correlations in migraine research. Eletriptan is supplied with detailed characterization data compliant with regulatory guidelines, and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility.

Product Parameters

Effect

Application

Product Advantages

Eletriptan demonstrates >6-fold higher 5-HT₁D affinity compared to sumatriptan, making it the most efficacious oral triptan for 2-hour pain freedom—the highest clinical benchmark for novel migraine agent comparison. This superior receptor binding translates to reliable and rapid migraine relief in clinical practice.

 Favorable Pharmacokinetic Profile

Eletriptan exhibits linear pharmacokinetics with rapid oral absorption (tₘₐₓ ~1 hour) and a terminal half-life of approximately 4–5 hours. This predictable PK profile simplifies dose-response correlations and supports consistent therapeutic outcomes in migraine management.

 Lipophilic Indole Scaffold

The indole core with phenylsulfonyl and N-methylpyrrolidine substituents gives Eletriptan a LogP of 4.839, enabling efficient central nervous system penetration—a critical requirement for acute migraine therapy where rapid brain exposure is essential for efficacy.

 Dual-Use: API and Analytical Reference Standard

Eletriptan serves as both the active pharmaceutical ingredient for commercial Relpax® production and as a reference standard for analytical method development, method validation (AMV), quality control (QC) applications for ANDA, and commercial production. Comprehensive characterization data compliant with regulatory guidelines supports both applications.

 Established Clinical Efficacy

Contact Us